chronic kidney disease
-
MedCity Influencers, Health Tech
The cavalry has arrived for the kidney care revolution: Policymakers, start-ups join physicians’ longstanding fight to transform a troubled industry
To combat challenges facing the industry, both policymakers and entrepreneurs have been working on complementary strategies to help primary care physicians, nephrologists and other care team members disrupt the status quo.
-
Regenerative med biotech ProKidney inks merger to get $825M for CKD cell therapy
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
CSL shakes off pandemic woes, diversifies with $11.7B Vifor Pharma acquisition
CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. In acquiring Vifor Pharma, CSL not only diversifies, it also expands its presence in the fast-growing nephrology market.
-
Vifor Pharma adds to chronic kidney disease lineup with pair of acquisitions
Nephrology products company Vifor Pharma is shelling out about $252 million combined up front to acquire Sanifit Therapeutics and Inositec, developers of drugs for a blood vessel complication affecting some chronic kidney disease patients. Both biotechs are in clinical trials with their respective lead drug candidates.
-
BioPharma, MedCity Influencers, SYN
Why there is great need for additional treatments to manage hyperphosphatemia in patients with CKD on dialysis
Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially address.
-
FDA approves first drug for severe itching in chronic kidney disease patients
Chronic kidney disease patients who experience pruritus after dialysis can now get relief from the first FDA-approved treatment for the condition. Cara Therapeutics received the FDA’s green light for its injectable drug, Korsuva.
-
FDA turns down Ardelyx’s chronic kidney disease drug and asks for another trial
Ardelyx drug tenapanor was rejected by the FDA as a treatment for a complication experienced by chronic kidney disease patients. The regulatory decision came two weeks after the company received an FDA letter citing deficiencies in the drug application.
-
Bayer kidney disease drug gets FDA nod, pitting it against AstraZeneca, J&J meds
The FDA has approved Bayer’s Kerendia to treat chronic kidney disease in patients with type 2 diabetes. The drug is the first in its class, giving the pharma giant an alternative way to compete against medicines already marketed by AstraZeneca and Johnson & Johnson.
-
In-home kidney care startup Monogram raises $160M
Monogram Health, a Tennessee-based startup that offers in-home care services for patients with chronic kidney disease raised $160 million in funding. The startup plans to use the funds to fuel its expansion across the U.S.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Congress: Pass the RAISE Act to address health disparities, advance health Equity in kidney care
As the nation continues to reckon with disparities in health, we have a real opportunity to remove barriers to proper kidney care.
-
Startup targets orphan kidney disease with former Merck drug
Vera Therapeutics licensed the drug candidate after analysis of earlier trials revealed its promise. Boosted by $80 million in Series C funding, the company hopes to launch a phase 2B trial this year.
-
MedCity Influencers, Artificial Intelligence
AI predicts better kidney care
AI models offer an early look into who might develop kidney disease, who would benefit from early intervention, and the risk of further complications without a change in course. However, it is worth taking a close look to ensure any bias or gaps are addressed.
-
Devices & Diagnostics, Health Services, Health Tech
CVS launches clinical trial for at-home hemodialysis device
CVS Health’s new HemoCare device would open up the at-home market for hemodialysis, which uses an artificial kidney device to perform the procedure and has traditionally been difficult to provide outside of a clinical setting.
-
President Trump aims to upend existing kidney care models through executive order
The executive order is focused on increasing the supply of kidneys available for transplants, improving prevention and treatment of chronic kidney disease and pushing the majority of dialysis patients to get their treatment through less-costly and more convenient home care.
-
Startups, Devices & Diagnostics, Diagnostics
Healthy.io raises $18M to bring smartphone urinalysis tech to U.S.
Healthy.io’s urinalysis testing kit – dubbed Dip.io – uses disposable strips and cups in conjunction with a smartphone camera to read and interpret results.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
